Literature DB >> 1399148

Genes involved in tumor invasion and metastasis are differentially modulated by estradiol and progestin in human breast-cancer cells.

F A van den Brûle1, J Engel, W G Stetler-Stevenson, F T Liu, M E Sobel, V Castronovo.   

Abstract

Invasion of basement membranes by cancer cells is a critical step in metastasis, which requires the coordinated expression of specific genes such as laminin receptors and metalloproteinases. Estradiol and progesterone modulate the clinical progression of steroid-sensitive breast cancers; however, little is known about the molecular regulation of the invasive phenotype by these hormones. We therefore examined the effects of 10 nM estradiol and/or 10 nM progestin R5020 on the expression of 2 non-integrin laminin binding proteins, the 67-kDa laminin receptor (67LR) and HLBP31 as well as the 72-kDa type-IV collagenase (MMP-2) and its inhibitor, TIMP-2, in steroid-receptor-positive (T47D and MCF-7) and -negative (MDA-MB 231) human breast-cancer cells. The relative steady-state level of 67LR mRNA was increased 2- to 3-fold by estradiol in both MCF-7 (p < 0.001) and T47D (p < 0.001) cells, also by R5020, alone or in combination with estradiol, in T47D cells (p < 0.001) and to a much less extent in MCF-7 cells. HLBP31 mRNA and protein levels were increased 2- to 3-fold (p < 0.001) by R5020 alone or in combination with estradiol, but not by estradiol alone. None of the steroid treatments affected the expression or activity of MMP-2. Interestingly, however, TIMP-2 mRNA levels and protein expression in MCF-7 and T47D cells were 50% down-regulated (p < 0.001) by treatment with R5020 or R5020 plus estradiol, but not by treatment with estradiol alone. None of these genes were modulated in steroid-independent MDA-MB231 cells. The data suggest that estradiol and progesterone might act as coordinators regulating specific genes in the steroid-sensitive breast-cancer cell, leading to the acquisition of the metastatic phenotype.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1399148     DOI: 10.1002/ijc.2910520426

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  Technical considerations for studying cancer metastasis in vivo.

Authors:  D R Welch
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

Review 2.  The role of estrogen receptors in breast cancer metastasis.

Authors:  S A Fuqua
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

3.  Expression of galectin-3 correlates with apoptosis in pituitary adenoma cells.

Authors:  Chui-Xue Huang; Yong-Hong Hou; Yun-Sheng Liu
Journal:  Neurosci Bull       Date:  2008-02       Impact factor: 5.203

4.  Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1, and vascular cell adhesion molecule type 1.

Authors:  M C Cid; H K Kleinman; D S Grant; H W Schnaper; A S Fauci; G S Hoffman
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

5.  Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells.

Authors:  Joan S Lewis-Wambi; Heather E Cunliffe; Helen R Kim; Amanda L Willis; V Craig Jordan
Journal:  Eur J Cancer       Date:  2008-07-07       Impact factor: 9.162

6.  17Beta-estradiol promotes aggressive laryngeal cancer through membrane-associated estrogen receptor-alpha 36.

Authors:  Nofrat Schwartz; Reyhaan A Chaudhri; Agreen Hadadi; Zvi Schwartz; Barbara D Boyan
Journal:  Horm Cancer       Date:  2013-10-01       Impact factor: 3.869

Review 7.  Matrix-degrading proteases in hormone-dependent breast cancer.

Authors:  R B Dickson; Y E Shi; M D Johnson
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

8.  Gelatinase A activity directly modulates melanoma cell adhesion and spreading.

Authors:  J M Ray; W G Stetler-Stevenson
Journal:  EMBO J       Date:  1995-03-01       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.